• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定靶向 SARS-CoV2 主蛋白酶的突变抗性冷点。

Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease.

机构信息

Department of Human Genetics, Sidra Medicine, Doha, Qatar.

Department of Genetic Medicine, Weill Cornell Medical College, Doha, Qatar.

出版信息

IUBMB Life. 2021 Apr;73(4):670-675. doi: 10.1002/iub.2465. Epub 2021 Mar 22.

DOI:10.1002/iub.2465
PMID:33749986
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8250577/
Abstract

Mutations in the novel coronavirus SARS-CoV2 are the major concern as they might lead to drug/vaccine resistance. In the host cell, the virus largely depends on the main protease (M ) to regulate infection hence it is one of the most attractive targets for inhibitor design. However, >19,000 mutations in the M have already been reported. The mutations encompassing 282 amino acid positions and these "hotspots" might change the M structure, activity and potentially delay therapeutic strategies targeting M . Thus, here we identified 24 mutational "coldspots" where mutations have not been observed. We compared the structure-function relationship of these coldspots with several SARS-CoV2 M X-ray crystal structures. We found that three coldspot residues (Leu141, Phe185, and Gln192) help to form the active site, while seven (Gly2, Arg4, Tyr126, Lys137, Leu141, Leu286, and Leu287) contribute to dimer formation that is required for M activity. The surface of the dimer interface is more resistant to mutations compared to the active site. Interestingly, most of the coldspots are found in three clusters and forms conserved patterns when compared with other coronaviruses. Importantly, several conserved coldspots are available on the surface of the active site and at the dimer interface for targeting. The identification and short list of these coldspots offers a new perspective to target the SARS-CoV2 M while avoiding mutation-based drug resistance.

摘要

新型冠状病毒(SARS-CoV2)的突变是主要关注点,因为它们可能导致药物/疫苗耐药性。在宿主细胞中,病毒在很大程度上依赖于主蛋白酶(M)来调节感染,因此它是抑制剂设计最有吸引力的目标之一。然而,已经报道了 M 上超过 19000 个突变。这些“热点”涵盖 282 个氨基酸位置的突变可能会改变 M 的结构、活性,并可能延迟针对 M 的治疗策略。因此,我们在这里确定了 24 个未观察到突变的突变“冷点”。我们比较了这些冷点的结构-功能关系与几种 SARS-CoV2 M X 射线晶体结构。我们发现三个冷点残基(Leu141、Phe185 和 Gln192)有助于形成活性位点,而七个残基(Gly2、Arg4、Tyr126、Lys137、Leu141、Leu286 和 Leu287)有助于形成二聚体形成,这是 M 活性所必需的。与活性位点相比,二聚体界面的表面对突变更具抗性。有趣的是,大多数冷点存在于三个簇中,并与其他冠状病毒相比形成保守模式。重要的是,几个保守的冷点在活性位点和二聚体界面的表面上可用于靶向。这些冷点的鉴定和候选名单为靶向 SARS-CoV2 M 提供了一个新视角,同时避免了基于突变的耐药性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/efa40f6cca7d/IUB-73-670-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/16b799a5ca41/IUB-73-670-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/fe5ab625d344/IUB-73-670-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/efa40f6cca7d/IUB-73-670-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/16b799a5ca41/IUB-73-670-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/fe5ab625d344/IUB-73-670-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aa7/8251999/efa40f6cca7d/IUB-73-670-g003.jpg

相似文献

1
Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease.鉴定靶向 SARS-CoV2 主蛋白酶的突变抗性冷点。
IUBMB Life. 2021 Apr;73(4):670-675. doi: 10.1002/iub.2465. Epub 2021 Mar 22.
2
The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.SARS-CoV-2 主蛋白酶的二聚体-单体平衡受小分子抑制剂影响。
Sci Rep. 2021 Apr 29;11(1):9283. doi: 10.1038/s41598-021-88630-9.
3
Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.靶向设计 SARS-CoV-2 主蛋白酶的药物结合位点揭示了潜在的适应性特征。
Biochem Biophys Res Commun. 2021 May 28;555:147-153. doi: 10.1016/j.bbrc.2021.03.118. Epub 2021 Mar 26.
4
Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.SARS-CoV-2 和 SARS 冠状病毒 3CL 蛋白酶的别构调节作用在晶体结构组合中观察到。
J Mol Biol. 2021 Dec 3;433(24):167324. doi: 10.1016/j.jmb.2021.167324. Epub 2021 Oct 27.
5
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
6
A new inactive conformation of SARS-CoV-2 main protease.严重急性呼吸综合征冠状病毒2型主要蛋白酶的一种新的无活性构象。
Acta Crystallogr D Struct Biol. 2022 Mar 1;78(Pt 3):363-378. doi: 10.1107/S2059798322000948. Epub 2022 Feb 21.
7
High-throughput design of symmetrical dimeric SARS-CoV-2 main protease: structural and physical insights into hotspots for adaptation and therapeutics.高通量设计对称二聚体 SARS-CoV-2 主蛋白酶:适应性和治疗热点的结构和物理见解。
Phys Chem Chem Phys. 2022 Apr 20;24(16):9141-9145. doi: 10.1039/d2cp00171c.
8
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.基于荧光的高通量 SARS-CoV-2 3CL 报告酶测定法的建立。
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
9
Effect of pH on stability of dimer structure of the main protease of coronavirus-2.pH 值对冠状病毒主蛋白酶二聚体结构稳定性的影响。
Biophys Chem. 2022 Aug;287:106829. doi: 10.1016/j.bpc.2022.106829. Epub 2022 May 19.
10
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.

引用本文的文献

1
Exploring the Therapeutic Potential of Mushroom on SARS-CoV-2 Using Virtual Screening against M and In Vitro Validation of Cordycepin.通过针对M蛋白的虚拟筛选及虫草素的体外验证探索蘑菇对严重急性呼吸综合征冠状病毒2的治疗潜力
J Microbiol Biotechnol. 2025 Mar 26;35:e2411063. doi: 10.4014/jmb.2411.11063.
2
Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations.通过分子动力学模拟揭示一种新型SARS-CoV-2 Mpro和PLpro天然双重抑制剂的作用机制。
Nat Prod Bioprospect. 2025 Jan 4;15(1):3. doi: 10.1007/s13659-024-00486-4.
3
The SARS-CoV-2 M Dimer-Based Screening System: A Synthetic Biology Tool for Identifying Compounds with Dimerization Inhibitory Potential.

本文引用的文献

1
An Overview of the Crystallized Structures of the SARS-CoV-2.SARS-CoV-2 结晶结构概述。
Protein J. 2020 Dec;39(6):600-618. doi: 10.1007/s10930-020-09933-w. Epub 2020 Oct 24.
2
SARS-CoV-2 M inhibitors and activity-based probes for patient-sample imaging.SARS-CoV-2 M 抑制剂和基于活性的探针用于患者样本成像。
Nat Chem Biol. 2021 Feb;17(2):222-228. doi: 10.1038/s41589-020-00689-z. Epub 2020 Oct 22.
3
Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography.中子晶体学揭示 SARS-CoV-2 主蛋白酶的非寻常两性离子催化位点。
基于 SARS-CoV-2 M 二聚体的筛选系统:一种用于鉴定具有二聚化抑制潜力的化合物的合成生物学工具。
ACS Synth Biol. 2024 Feb 16;13(2):509-520. doi: 10.1021/acssynbio.3c00446. Epub 2024 Feb 5.
4
The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection.SARS-CoV-2 N-连接聚糖和关注的 Spike 蛋白突变对 C 型凝集素受体介导感染的影响。
Viruses. 2023 Sep 9;15(9):1901. doi: 10.3390/v15091901.
5
Bioprospecting phytochemicals of Rosmarinus officinalis L. for targeting SARS-CoV-2 main protease (M): a computational study.利用计算机研究迷迭香 Rosmarinus officinalis L. 的植物化学成分,以针对 SARS-CoV-2 主要蛋白酶(M)。
J Mol Model. 2023 Apr 28;29(5):161. doi: 10.1007/s00894-023-05569-6.
6
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.抗靶标,抗 SARS-CoV-2 先导物,药物,以及药物发现遗传学联盟的视角。
J Med Chem. 2023 Mar 23;66(6):3664-3702. doi: 10.1021/acs.jmedchem.2c01229. Epub 2023 Mar 1.
7
Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.结构基础:尼马曲韦和恩曲他韦对 SARS-CoV-2 主蛋白酶天然发生的多态性的活性。
J Biol Chem. 2023 Mar;299(3):103004. doi: 10.1016/j.jbc.2023.103004. Epub 2023 Feb 10.
8
A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2.评估小分子药物潜在抗病毒耐药性的策略及其在 SARS-CoV-2 中的应用。
Sci Rep. 2023 Jan 10;13(1):502. doi: 10.1038/s41598-023-27649-6.
9
Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶突变动力学的最新变化证实了对抗病毒药物产生耐药性的风险。
Front Med (Lausanne). 2022 Dec 14;9:1061142. doi: 10.3389/fmed.2022.1061142. eCollection 2022.
10
X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation.SARS-CoV-2 主要蛋白酶多蛋白切割位点的 X 射线晶体学表征,这些切割位点对于病毒的加工和成熟至关重要。
Nat Commun. 2022 Sep 3;13(1):5196. doi: 10.1038/s41467-022-32854-4.
J Biol Chem. 2020 Dec 11;295(50):17365-17373. doi: 10.1074/jbc.AC120.016154. Epub 2020 Oct 15.
4
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.SARS-CoV-2 主蛋白酶的晶体学和亲电片段筛选。
Nat Commun. 2020 Oct 7;11(1):5047. doi: 10.1038/s41467-020-18709-w.
5
Genomic and proteomic mutation landscapes of SARS-CoV-2.SARS-CoV-2 的基因组和蛋白质组突变景观。
J Med Virol. 2021 Mar;93(3):1702-1721. doi: 10.1002/jmv.26548. Epub 2020 Oct 8.
6
Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease.临床相关的 SARS-CoV-2 主蛋白酶变异体的序列特征和分子建模。
Biochemistry. 2020 Oct 6;59(39):3741-3756. doi: 10.1021/acs.biochem.0c00462. Epub 2020 Sep 24.
7
Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M.大流行早期突变对 SARS-CoV-2 M 分子动力学的影响。
J Chem Inf Model. 2020 Oct 26;60(10):5080-5102. doi: 10.1021/acs.jcim.0c00634. Epub 2020 Sep 16.
8
The SARS-CoV-2 main protease as drug target.SARS-CoV-2 主要蛋白酶作为药物靶点。
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127377. doi: 10.1016/j.bmcl.2020.127377. Epub 2020 Jul 2.
9
Structural plasticity of SARS-CoV-2 3CL M active site cavity revealed by room temperature X-ray crystallography.室温 X 射线晶体学揭示 SARS-CoV-2 3CL M 活性位点腔的结构可塑性。
Nat Commun. 2020 Jun 24;11(1):3202. doi: 10.1038/s41467-020-16954-7.
10
Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.靶向冠状病毒主蛋白酶的二聚化:一种有潜力的广谱治疗策略。
ACS Comb Sci. 2020 Jun 8;22(6):297-305. doi: 10.1021/acscombsci.0c00058. Epub 2020 May 27.